Offer - Urjas Oil for just ₹ 1 X
Cecort (Optica) is a prescription drug, available for use as Ointment. Secondary and off-label uses of Cecort (Optica) have also been mentioned below.
Medical history of the patient along with age and gender determines the dosage of Cecort (Optica). Dosage also depends on the route of administration and your chief complaint for which the drug is prescribed. For detailed information on this, read through the dosage section.
Cecort (Optica) also has some side effects, the most common being Facial swelling, Muscle cramps or spasms (painful), Abdominal Pain. Apart from the aforementioned side effects, Cecort (Optica) can also lead to other problems, which have been listed below. Normally, these side effects of Cecort (Optica) are not long lasting and go away when the treatment is finished. If, however, they worsen or do not go away, please speak with your physician.
It is also important to note that Cecort (Optica) has a Moderate effect for pregnant women and Unknown effect on lactating mothers. Warnings related to Cecort (Optica)'s effects on the liver, heart and kidney, if any, have been listed below.
Individuals suffering from medical conditions like Kidney Disease, Liver Disease must refrain from the use of Cecort (Optica) since this can cause severe adverse effects. Some other conditions that can be affected by Cecort (Optica) are listed in the contraindications section below.
Drug interactions for Cecort (Optica) have been reported in the medical literature. See below for a complete list.
Along with the above-mentioned precautions, remember that taking Cecort (Optica) is considered safe while driving, and is addictive.
Cecort (Optica) is used to treat the following -
Other Benefits
This is the usual dosage recommended in most common treatment cases. Please remember that every patient and their case is different, so the dosage can be different based on the disease, route of administration, patient's age and medical history.
Find the right dosage based on disease and age
Age Group | Dosage |
13 - 18 years (Adolescent) |
|
Adult |
|
Geriatric |
|
Is the use of Cecort (Optica) safe for pregnant women?
Cecort (Optica) can have harmful effects in pregnant women. If you experience any discomfort after using Cecort (Optica), then discontinue the use and take your doctor's advice.
Is the use of Cecort (Optica) safe during breastfeeding?
In the absence of any scientific study about the side effects of Cecort (Optica) in breastfeeding women, information on safety of Cecort (Optica) is unavailable.
What is the effect of Cecort (Optica) on the Kidneys?
Cecort (Optica) may cause harmful effects on kidney. if you feel its having any such effect, then stop taking this drug, and restart only on your doctor's advice.
What is the effect of Cecort (Optica) on the Liver?
Cecort (Optica) may cause harmful effects on liver. if you feel it's having any such effect, then stop taking this drug, and restart only on your doctor's advice.
What is the effect of Cecort (Optica) on the Heart?
Cecort (Optica) can have moderate side effects on the heart. If you notice any harmful effects then stop taking this drug right away. Consult your doctor before using this medicine again.
Cecort (Optica) should not be taken with following medicines due to severe side effects it may cause to patients -
Moderate
If you are suffering from any of the following diseases, you should not take Cecort (Optica) unless your doctor advises you to do so -
Is this Cecort (Optica) habit forming or addictive?
Cecort (Optica) does not cause addiction.
Interaction between Food and Cecort (Optica)
Due to a lack of research, nothing can be said about the consequences of taking Cecort (Optica) together with food.
Interaction between Alcohol and Cecort (Optica)
It is difficult to say anything about the effect of Cecort (Optica) and alcohol. No research has been done on this yet.
Take Cecort (Optica) as directed by your doctor to ensure complete eradication of infection. Do not take this medicine longer than prescribed to avoid bacterial resistance.
No, Cecort (Optica) does not cause weight loss. It has not been reported by the patients who are taking this drug. However, some of the animal studies have reported weight loss after long-term use of this drug. If you are experiencing unusual weight loss and you are in doubt that Cecort (Optica) is causing weight loss then discuss with your doctor instantly.
No, Cecort (Optica) does not cover Enterococcus faecalis. They are generally found to be resistant to Cecort (Optica). However antibiotic sensitivity test is recommended to confirm its resistance.
Yes, Cecort (Optica) may cause gray baby syndorme in newborn infants especially in premature baby, if this drug is given in higher doses. Gray baby syndrome is a rare side effect that occurs due to accumulation of the chloramphenicol in the newborn infant. The cause of gray baby syndrome is that the newborn baby lacks the some liver enzymes which are necessary to metabolize and removes this drug from the body. The accumulation of the chloramphenicol in the body leads to toxicity which causes development of symptoms such as vomiting, gray color of the skin, blue discolouration of lips and skin. To avoid gray baby syndrome the doses of Cecort (Optica) must be lowered and adjusted as per the need.
Yes, Cecort (Optica) might cause aplastic anemia which is a type of anemia in which the body is not able to make new red blood cells. Cecort (Optica) induces aplastic anemia by suppressing the red bone marrow which produces new red blood cells. However, it is reversible and the red blood cells production by red bone marrow is restored after discontinuation of this drug.
This medicine data has been created by -
B.Pharma, Pharmacy
5 Years of Experience
References
US Food and Drug Administration (FDA) [Internet]. Maryland. USA; Package leaflet information for the user; Chloromycetin sodium succinate (chaloramphenicol sodium succinate)
KD Tripathi. [link]. Seventh Edition. New Delhi, India: Jaypee Brothers Medical Publishers; 2013: Page No 739-742
April Hazard Vallerand, Cynthia A. Sanoski. [link]. Sixteenth Edition. Philadelphia, China: F. A. Davis Company; 2019: Page No 362-366
KD Tripathi. [link]. Seventh Edition. New Delhi, India: Jaypee Brothers Medical Publishers; 2013: Page No 288
US Food and Drug Administration (FDA) [Internet]. Maryland. USA; Package leaflet information for the user; Cortef® (hydrocortisone)
US Food and Drug Administration (FDA) [Internet]. Maryland. USA; Package leaflet information for the user; Solu-Cortef® (hydrocortisone sodium succinate)
US Food and Drug Administration (FDA) [Internet]. Maryland. USA; Package leaflet information for the user; Pandel (hydrocortisone probutate)
US Food and Drug Administration (FDA) [Internet]. Maryland. USA; Package leaflet information for the user; Cortenema® (hydrocortisone)